Zhengye Biotechnology Holding (ZYBT) Receivables - Net (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Receivables - Net for 3 consecutive years, with $5.1 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Receivables - Net fell 51.61% year-over-year to $5.1 million in Q4 2025; TTM through Dec 2025 was $5.1 million, a 51.61% decrease from a year earlier, with the FY2025 full-year figure at $5.2 million, down 50.13% from the prior year.
• Receivables - Net was $5.1 million for Q4 2025 at Zhengye Biotechnology Holding, down from $7.4 million in the prior quarter.
• Over five years, Receivables - Net peaked at $12.9 million in Q4 2023 and troughed at $5.1 million in Q4 2025.
• A 3-year average of $9.0 million and a median of $9.0 million in 2024 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net declined 17.42% in 2024 and slumped 51.61% in 2025, its largest moves.
• Over 3 years, Receivables - Net stood at $12.9 million in 2023, then fell by 17.42% to $10.6 million in 2024, then tumbled by 51.61% to $5.1 million in 2025.
• The last three Receivables - Net figures came in at $5.1 million (Q4 2025), $7.4 million (Q2 2025), and $10.6 million (Q4 2024), per Business Quant data.